CL2016001111A1 - Formulaciones de compuestos de azaindol. - Google Patents
Formulaciones de compuestos de azaindol.Info
- Publication number
- CL2016001111A1 CL2016001111A1 CL2016001111A CL2016001111A CL2016001111A1 CL 2016001111 A1 CL2016001111 A1 CL 2016001111A1 CL 2016001111 A CL2016001111 A CL 2016001111A CL 2016001111 A CL2016001111 A CL 2016001111A CL 2016001111 A1 CL2016001111 A1 CL 2016001111A1
- Authority
- CL
- Chile
- Prior art keywords
- formulations
- influenza
- azaindole compounds
- azaindole
- compounds
- Prior art date
Links
- 125000005334 azaindolyl group Chemical class N1N=C(C2=CC=CC=C12)* 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 206010022000 influenza Diseases 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361903840P | 2013-11-13 | 2013-11-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001111A1 true CL2016001111A1 (es) | 2017-06-09 |
Family
ID=52001095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001111A CL2016001111A1 (es) | 2013-11-13 | 2016-05-10 | Formulaciones de compuestos de azaindol. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20160250213A1 (enExample) |
| EP (1) | EP3068434A1 (enExample) |
| JP (2) | JP2016537347A (enExample) |
| KR (1) | KR20160084465A (enExample) |
| CN (1) | CN105848683A (enExample) |
| AU (1) | AU2014348762A1 (enExample) |
| CA (1) | CA2930105A1 (enExample) |
| CL (1) | CL2016001111A1 (enExample) |
| IL (2) | IL245587A0 (enExample) |
| MX (1) | MX2016006197A (enExample) |
| RU (1) | RU2685730C1 (enExample) |
| SG (1) | SG10201804024VA (enExample) |
| WO (1) | WO2015073491A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20207129B (en) | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| HRP20191525T1 (hr) | 2013-11-13 | 2019-11-29 | Vertex Pharma | Inhibitori replikacije virusa influence |
| EP3421468B1 (en) | 2013-11-13 | 2020-11-04 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
| JP6704416B2 (ja) | 2015-05-13 | 2020-06-03 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インフルエンザウイルスの複製の阻害剤を調製する方法 |
| WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
| EP3362451B1 (en) | 2015-12-09 | 2023-04-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| WO2018033082A1 (en) | 2016-08-16 | 2018-02-22 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
| CN109641868B (zh) | 2016-08-30 | 2021-12-03 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
| JP7034162B2 (ja) * | 2016-12-15 | 2022-03-11 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | インフルエンザウイルス複製の阻害剤及びその使用 |
| WO2018127096A1 (en) | 2017-01-05 | 2018-07-12 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
| US10815232B2 (en) | 2017-01-24 | 2020-10-27 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline forms of viral-protein inhibitor drug VX-787, processes for preparation thereof and use thereof |
| CN110446711B (zh) | 2017-03-02 | 2022-02-15 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
| EP3609502A1 (en) * | 2017-04-12 | 2020-02-19 | Vertex Pharmaceuticals Incorporated | Combination therapies for treating influenza virus infection |
| WO2019043614A1 (en) * | 2017-08-31 | 2019-03-07 | Novartis Ag | PROCESS FOR THE PREPARATION OF GRANULES |
| US20210147413A1 (en) * | 2018-04-06 | 2021-05-20 | Janssen Pharmaceuticals, Inc. | Isothermal reactive crystallisation process for the preparation of a crystalline form of pimodivir hydrochloride hemihydrate |
| WO2020058745A1 (en) * | 2018-09-18 | 2020-03-26 | Shionogi & Co., Ltd. | Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof |
| US12156876B2 (en) * | 2018-11-13 | 2024-12-03 | Cocrystal Pharma, Inc. | Formulations of influenza therapeutics |
| KR20200106607A (ko) * | 2019-03-05 | 2020-09-15 | 주식회사 코아팜바이오 | 오셀타미비르 함유 의약 조성물 |
| WO2020256820A1 (en) * | 2019-06-20 | 2020-12-24 | Janssen Pharmaceuticals, Inc. | Formulations of azaindole compounds |
| CN112578034B (zh) * | 2020-11-04 | 2022-02-11 | 广东众生睿创生物科技有限公司 | 一种手性胺小分子及其盐的质量控制方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681815A (en) * | 1993-06-28 | 1997-10-28 | Sophie Chen | Antiviral and antitumor agents |
| EP2486942B1 (en) * | 2004-11-24 | 2018-10-10 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
| WO2010143207A1 (en) * | 2009-06-11 | 2010-12-16 | Rubicon Research Private Limited | Taste-masked oral formulations of influenza antivirals |
| GEP20207129B (en) * | 2009-06-17 | 2020-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
-
2014
- 2014-11-12 MX MX2016006197A patent/MX2016006197A/es unknown
- 2014-11-12 WO PCT/US2014/065144 patent/WO2015073491A1/en not_active Ceased
- 2014-11-12 JP JP2016529960A patent/JP2016537347A/ja active Pending
- 2014-11-12 SG SG10201804024VA patent/SG10201804024VA/en unknown
- 2014-11-12 EP EP14805749.0A patent/EP3068434A1/en not_active Withdrawn
- 2014-11-12 CA CA2930105A patent/CA2930105A1/en not_active Abandoned
- 2014-11-12 CN CN201480071163.7A patent/CN105848683A/zh active Pending
- 2014-11-12 AU AU2014348762A patent/AU2014348762A1/en not_active Abandoned
- 2014-11-12 KR KR1020167015721A patent/KR20160084465A/ko not_active Ceased
- 2014-11-12 RU RU2016122609A patent/RU2685730C1/ru active
-
2016
- 2016-05-10 CL CL2016001111A patent/CL2016001111A1/es unknown
- 2016-05-10 IL IL245587A patent/IL245587A0/en unknown
- 2016-05-10 US US15/150,497 patent/US20160250213A1/en not_active Abandoned
-
2018
- 2018-07-16 US US16/036,044 patent/US20180318301A1/en not_active Abandoned
-
2020
- 2020-09-30 US US17/038,749 patent/US20210008072A1/en not_active Abandoned
- 2020-10-21 IL IL278214A patent/IL278214A/en unknown
-
2021
- 2021-09-17 JP JP2021152005A patent/JP2021191796A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016537347A (ja) | 2016-12-01 |
| RU2685730C1 (ru) | 2019-04-23 |
| WO2015073491A1 (en) | 2015-05-21 |
| RU2016122609A (ru) | 2017-12-18 |
| CN105848683A (zh) | 2016-08-10 |
| KR20160084465A (ko) | 2016-07-13 |
| SG10201804024VA (en) | 2018-07-30 |
| US20160250213A1 (en) | 2016-09-01 |
| IL278214A (en) | 2020-11-30 |
| EP3068434A1 (en) | 2016-09-21 |
| JP2021191796A (ja) | 2021-12-16 |
| AU2014348762A1 (en) | 2016-05-26 |
| IL245587A0 (en) | 2016-06-30 |
| MX2016006197A (es) | 2016-08-08 |
| US20210008072A1 (en) | 2021-01-14 |
| US20180318301A1 (en) | 2018-11-08 |
| CA2930105A1 (en) | 2015-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001111A1 (es) | Formulaciones de compuestos de azaindol. | |
| GT201500021A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2014000245A1 (es) | Compuestos derivados de heterociclos nitrogenados, inhibidores de replicacion de los virus de influenza; metodo de preparacion; composicionn farmaceutica; metodo para inhibir la replicacion del virus de la influenza en una muestra biológica o un paciente. | |
| CL2016000952A1 (es) | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2014003634A1 (es) | Inhibidores del virus de la hepatitis c | |
| BR112017002811A2 (pt) | compostos de pirrolopirimidina usados como agonista de tlr7 | |
| EA201591166A1 (ru) | Ингибиторы аутотаксина | |
| GT201400009A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| CL2016001737A1 (es) | Derivados heterocíclicos bicíclicos como inhibidores de bromodominio | |
| CO2019009215A2 (es) | Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| MX2016003216A (es) | Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b. | |
| MX357423B (es) | Sistema de desecho de medicamento general. | |
| ECSP16059106A (es) | Composiciones de liberación retardada de linaclotida | |
| CL2014001110A1 (es) | Compuestos derivados de piperazin-piridin-bifenil-imidazol-pirrolidinas sustituidas, inhibidores de la replicacion del virus de la hepatitis c (hcv); composicion farmaceutica que los comprende; proceso para preparar un compuesto; metodo para tratar una infeccion del virus hcv; y uso para tratar una infeccion del virus hcv. | |
| CL2016000063A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| DOP2016000253A (es) | Nuevos compuestos | |
| CL2016000148A1 (es) | Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| CL2015003468A1 (es) | Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d. | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| CL2017000587A1 (es) | Derivados de tetrahidroquinolina como inhibidores de bromodominio | |
| UY36329A (es) | NUEVOS DERIVADOS BICÍCLICOS QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENÉRGICOS ß2 Y COMO ANTAGONISTAS MUSCARÍNICOS M3 |